We provide evidence that the coinhibitory molecule CTLA-4 plays a critical role in limiting the development of angiotensin II-induced AAA and reducing the mortality by suppressing immunoinflammatory responses in the aortic aneurysmal lesions. Here, CTLA4 is linked to triple-A syndrome.